Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter Randomized Double blind Placebo controlled Study with a Long-term Open-label Extension
Brief description of study
Efficacy of nipocalimab in
patients with warm autoimmune
hemolytic anemia (wAIHA)
Durable response in improvement in hemoglobin (Hgb),
defined as attainment of the following at 3 consecutive
visits, where at least the first is at or before Week 16,
without the need of rescue therapy:
1- Hgb concentration greater than or equal to10 g/dL AND
2- An increase from baseline in Hgb greater than or equal to 2 g/dL Durable response in improvement in hemoglobin (Hgb),
defined as attainment of the following at 3 consecutive
visits, where at least the first is at or before Week 16,
without the need of rescue therapy:
1- Hgb concentration greater than or equal to10 g/dL AND
2- An increase from baseline in Hgb greater than or equal to 2 g/dL -Change from baseline in the total score from the Functional
Assessment of Chronic Illness Therapy-Fatigue (FACITFatigue)
Scale at the end of the double-blind period
-Simultaneous attainment of normal lactate dehydrogenase
(LDH), AND normal haptoglobin, AND normal indirect
bilirubin levels at a minimum of 3 consecutive visits after
baseline
-Percent reduction from baseline in daily dose of prednisone
or equivalent at week 24 among patients on prednisone or
equivalent at baseline
-Hgb range at steady state (estimated using a model-based
longitudinal analysis of Hgb/hemolysis parameters in
relationship to IgG level and dose regimen)
-Hemoglobin concentration, reticulocyte count,
hemolytic markers, and change from baseline in these
parameters through Week 16 of the double-blind period
-Hemoglobin concentration, reticulocyte count,
hemolytic markers, and change from baseline
throughout the study
-Attainment of the following at any time during the
study:
An increase from baseline in Hgb of greater than or equal to 2 g/dL AND
normal LDH, haptoglobin, and indirect bilirubin levels
- Attainment of the above at 3 consecutive visits
-Time to response defined as the first time point at
which the criteria for the primary efficacy endpoint are
met
- Duration from the first time point at which the durable
response criteria for the primary efficacy endpoint are
met until the time point at which it is no longer met
-Change from baseline in the total score from the
FACIT-Fatigue Scale at the time of durable response
- Change from baseline in the total score and item scores
from the FACIT-Fatigue Scale during the double-blind
period and open-label extension (OLE)
-EuroQol 5-dimension, 5-level (EQ-5D-5L) quality of life
questionnaire, Medical Outcomes Study Short Form
36-Item health survey (SF-36), patient global impression of
severity (PGIS), patient global impression of change
(PGIC), and FACIT-Fatigue Scale
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
11 Jan 2023.
Study ID: 850609
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting